Kari Hemminki1, Kamila Czene. 1. Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden. kari.hemminki@cnt.ki.se
Abstract
BACKGROUND: Familial risks by proband status and age are useful for clinical counseling, and they can be used to calculate population-attributable fractions (PAFs), which show the proportion of disease that could be prevented if the cause could be removed. METHODS: The authors used the nationwide Swedish Family-Cancer Database on 10.2 million individuals and 182,104 fathers and 3710 sons with medically verified prostate carcinoma to calculate age specific familial standardized incidence ratios (SIRs) with 95% confidence intervals (95%CI) and familial PAFs for prostate carcinoma in sons ages 0-66 years. RESULTS: The incidence of prostate carcinoma was doubled between the years 1961 and 1998. The familial SIRs for prostate carcinoma were 2.38 (95%CI, 2.18-2.59) for men with prostate carcinoma in the father only, 3.75 (95%CI, 2.73-4.95) for men with prostate carcinoma in a brother only, and 9.44 (95%CI, 5.76-14.03) for men with prostate carcinoma in both a father and a brother. The corresponding familial PAFs were 8.86%, 1.78%, and 0.99%, respectively, yielding a total PAF of 11.63%. Age specific risks were shown for the same proband histories. The SIR was 8.05 for prostate carcinoma before age 55 if a brother had been diagnosed before that age. If, in addition, a father was diagnosed at any age, then the SIR was 33.09. CONCLUSIONS: The authors recommend that having a brother who is diagnosed with prostate carcinoma before age 55 years or having a brother and father who are diagnosed at any age are indications to screen for prostate carcinoma. The familial PAF of prostate carcinoma among a population of sons ages 0-66 years was 11.63%. Copyright 2002 American Cancer Society.
BACKGROUND: Familial risks by proband status and age are useful for clinical counseling, and they can be used to calculate population-attributable fractions (PAFs), which show the proportion of disease that could be prevented if the cause could be removed. METHODS: The authors used the nationwide Swedish Family-Cancer Database on 10.2 million individuals and 182,104 fathers and 3710 sons with medically verified prostate carcinoma to calculate age specific familial standardized incidence ratios (SIRs) with 95% confidence intervals (95%CI) and familial PAFs for prostate carcinoma in sons ages 0-66 years. RESULTS: The incidence of prostate carcinoma was doubled between the years 1961 and 1998. The familial SIRs for prostate carcinoma were 2.38 (95%CI, 2.18-2.59) for men with prostate carcinoma in the father only, 3.75 (95%CI, 2.73-4.95) for men with prostate carcinoma in a brother only, and 9.44 (95%CI, 5.76-14.03) for men with prostate carcinoma in both a father and a brother. The corresponding familial PAFs were 8.86%, 1.78%, and 0.99%, respectively, yielding a total PAF of 11.63%. Age specific risks were shown for the same proband histories. The SIR was 8.05 for prostate carcinoma before age 55 if a brother had been diagnosed before that age. If, in addition, a father was diagnosed at any age, then the SIR was 33.09. CONCLUSIONS: The authors recommend that having a brother who is diagnosed with prostate carcinoma before age 55 years or having a brother and father who are diagnosed at any age are indications to screen for prostate carcinoma. The familial PAF of prostate carcinoma among a population of sons ages 0-66 years was 11.63%. Copyright 2002 American Cancer Society.
Authors: J-A Thomas; L Gerber; D M Moreira; R J Hamilton; L L Bañez; R Castro-Santamaria; G L Andriole; W B Isaacs; J Xu; S J Freedland Journal: J Intern Med Date: 2012-01-16 Impact factor: 8.989
Authors: Roberto L Muller; Eliney F Faria; Gustavo F Carvalhal; Rodolfo B Reis; Edmundo C Mauad; Andre L Carvalho; Stephen J Freedland Journal: World J Urol Date: 2012-07-21 Impact factor: 4.226
Authors: Z Kote-Jarai; D Leongamornlert; M Tymrakiewicz; H Field; M Guy; A A Al Olama; J Morrison; L O'Brien; R Wilkinson; A Hall; E Sawyer; K Muir; F Hamdy; J Donovan; D Neal; D Easton; R Eeles Journal: Br J Cancer Date: 2009-12-08 Impact factor: 7.640
Authors: Nandu D Dantanarayana; Tania Hossack; Paul Cozzi; Andrew Brooks; Howard Lau; Warick Delprado; Manish I Patel Journal: BMC Urol Date: 2015-12-30 Impact factor: 2.264